Philip Prathipati - Concepedia

Author

Philip Prathipati

Central Drug Research Institute ORCID

Also Known As

P. Prathipati, Philip Prathipati, Prathipati, Philip, Priyanka Prathipati

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Central Drug Research Institute National Institute of Biomedical Innovation, Health and Nutrition University of Madras Novartis (Singapore)Chuo University

About

Philip Prathipati is an author at Central Drug Research Institute specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	454
2	Natural Sciences	10	10	375
3	Biochemistry	9	9	382
4	Engineering	3	3	121
5	Biomolecular Engineering	2	2	69

Philip Prathipati

Publications

846

Citations

H-Index

Page 1

	Year	Citations
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos Tadigoppula Narender, Shweta Shweta, Piyush Tiwari, Bioorganic & Medicinal Chemistry Letters Lipid AnalysisMedicinal ChemistryBiochemistryNatural SciencesAegle Marmelos	2006	134
Comparison of MLR, PLS and GA-MLR in QSAR analysis* Shailendra K. Saxena, Philip Prathipati SAR and QSAR in environmental research EngineeringVariable SelectionData ScienceGenetic AlgorithmBiostatistics	2003	98
Global Bayesian Models for the Prioritization of Antitubercular Agents Philip Prathipati, Ngai Ling, Thomas H. Keller Journal of Chemical Information and Modeling	2008	95
Computer-Aided Drug Design: Integration of Structure-Based and Ligand-Based Approaches in Drug Design Philip Prathipati, Anshuman Dixit, Anil K. Saxena Current Computer - Aided Drug Design Pharmaceutical ResearchDrug TargetHit IdentificationVirtual Screening TechniquesMolecular Design	2007	56
Identification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target Shuntaro Chiba, Kazuyoshi Ikeda, Takashi Ishida, Scientific Reports Drug TargetHit IdentificationTyrosine-protein Kinase YesChemical BiologyMedicinal Chemistry	2015	46
Development of 3D-QSAR models for 5-Lipoxygenase antagonists: chalcones M. Arockia Babu, Neeraj Shakya, Philip Prathipati, Bioorganic & Medicinal Chemistry Molecular DockingBiochemistryMedicineRational Drug Design3D-qsar Models	2002	43
miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma Anup S. Pathania, Philip Prathipati, Omalla A. Olwenyi, Molecular Therapy — Oncolytics	2022	35
Evaluation of Binary QSAR Models Derived from LUDI and MOE Scoring Functions for Structure Based Virtual Screening Philip Prathipati, Anil K. Saxena Journal of Chemical Information and Modeling	2005	34
A prospective compound screening contest identified broader inhibitors for Sirtuin 1 Shuntaro Chiba, Masahito Ohue, Anastasiia Gryniukova, Scientific Reports	2019	33
Characterization of β3-adrenergic receptor: determination of pharmacophore and 3D QSAR model for β3 adrenergic receptor agonism Philip Prathipati, Anil K. Saxena Journal of Computer-Aided Molecular Design Molecular PharmacologyFunctional SelectivityMedicinePhysiologyQsar Model	2005	29

Page 1